openPR Logo
Press release

Creative Diagnostics Announces Respiratory Syncytial Virus Animal Models to Advance RSV Research

08-27-2024 07:42 PM CET | Health & Medicine

Press release from: ABNewswire

Creative Diagnostics Announces Respiratory Syncytial Virus

Creative Diagnostics launches advanced Respiratory Syncytial Virus Animal Models for researchers and scientists worldwide.
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced the launch of its advanced Respiratory Syncytial Virus Animal Models [https://antiviral.creative-diagnostics.com/respiratory-syncytial-virus-animal-model.html] for researchers and scientists worldwide focused on advancing RSV research and accelerating the development of effective vaccines and therapeutics against RSV.

Human respiratory syncytial virus (hRSV) is an enveloped, single-stranded, negative-sense RNA virus that represents a significant public health burden in both developing and developed countries. Scientists have made concerted efforts to develop various animal models to study different aspects of hRSV. However, the high specificity of hRSV for the human host has greatly hindered the development of specialized animal models. In addition, because no single animal model reflects all aspects of this viral infection and disease, a variety of models have been used to study RSV, ranging from rodents and small mammals to large animals and non-human primates (NHPs).

With the exception of chimpanzees, nonhuman primates are only partially susceptible to hRSV replication. After infection, nonhuman primates have mild or no clinical signs and generally show mild lung lesions. Cotton rats, mice, ferrets, chinchillas, guinea pigs, hamsters, and newborn lambs are also not susceptible to RSV infection. Additionally, cotton rats and mice have been invaluable in the development of monoclonal antibody prophylaxis for high-risk infants and have provided insights into RSV immunity and pathogenesis.

RSV animal models are important tools for studying the complex dynamics of RSV infection, evaluating potential therapies, and developing effective vaccines. With advanced animal modeling technology and unparalleled infectious disease expertise, Creative Diagnostics provides researchers and scientists with reliable respiratory syncytial virus animal models to facilitate the development of therapies and vaccines. Its team of experts can provide clients with the most appropriate RSV animal model based on the infection to be studied and the proposed research hypothesis.

Creative Diagnostics offers a full range of services to support RSV animal model research, including study design and execution, pathological analysis and immune response profiling, as well as in vivo pharmacokinetic studies and pharmacodynamics/efficacy/toxicity assessments. These RSV animal model services allow scientists to evaluate the immunogenicity and efficacy of potential RSV vaccine candidates in preclinical studies, investigate RSV pathogenesis to identify novel therapeutic targets, and assess the safety and efficacy of antiviral and immunomodulatory compounds.

With extensive expertise in biological research, Creative Diagnostics offers RSV Cotton Rat Models and RSV Mouse Models to advance RSV research, vaccine development, and drug discovery. By providing RSV animal models, Creative Diagnostics aims to help accelerate the development of effective treatments and improve patient outcomes. With this new offering, Creative Diagnostics reinforces its commitment to providing high-quality research tools and services to advance the understanding and treatment of infectious diseases.

For more information on the RSV animal models, please visit https://antiviral.creative-diagnostics.com/respiratory-syncytial-virus-animal-model.html.

About Creative Diagnostics

Headquartered in New York, Creative Diagnostics is a consulting and experimental service provider specializing in virology and microbiology. The company provides comprehensive solutions to conquer obstacles in virology and microbiology research, from high-security infrastructure provision, biosafety regulation elucidation, to expert viral system assistance.

Media Contact
Company Name: Creative Diagnostics
Contact Person: Thomas Schmitt
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=creative-diagnostics-announces-respiratory-syncytial-virus-animal-models-to-advance-rsv-research]
State: New York
Country: United States
Website: https://antiviral.creative-diagnostics.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Creative Diagnostics Announces Respiratory Syncytial Virus Animal Models to Advance RSV Research here

News-ID: 3636706 • Views:

More Releases from ABNewswire

98% Consistency, 0 Staff: Anno Robot Redefines Airport Coffee in 60 Countries
98% Consistency, 0 Staff: Anno Robot Redefines Airport Coffee in 60 Countries
As millions of travellers rush through terminals worldwide, one constant complaint has finally been solved: bad airport coffee served slowly by exhausted staff. Shenzhen-based Anno Robot [https://www.coffeerobotsanno.com/] has quietly eliminated both problems with fully robotic kiosks that deliver 98% brew-to-brew consistency and require zero human baristas. By November 2025, these AI-powered stations are operating in airports and high-traffic hubs across more than 60 countries, marking a turning point for the
FAXVIN Unveils Enhanced CarRank, a 0-100 Single-Score Summary That Makes Used-Car Decisions Faster
FAXVIN Unveils Enhanced CarRank, a 0-100 Single-Score Summary That Makes Used-Ca …
Updated methodology brings additional partner data and refined signal weighting so shoppers and dealers can rank and compare vehicles in seconds. WALNUT, Calif. - Nov. 19, 2025 - FAXVIN today announced a significant update to CarRank, its 0-100 vehicle-history metric designed to help shoppers and dealers compare used cars at a glance. The latest release incorporates additional data sources and methodology refinements that improve how risk signals are weighted across title
Global Pro AV Market Surges Toward USD 127.31 Billion by 2030, Led by Sony, Samsung, LG, Panasonic, Crestron | Arizton
Global Pro AV Market Surges Toward USD 127.31 Billion by 2030, Led by Sony, Sams …
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2025-2030. According to Arizton research, the global pro AV market [https://www.arizton.com/market-reports/pro-av-market] was valued at USD 90.00 billion in 2024 and is projected to reach USD 127.31 billion by 2030, growing at a CAGR of 5.95% during the forecast period. Explore the Full Market Insights: https://www.arizton.com/market-reports/pro-av-market Report Summary: Market Size (2030): USD 127.31 Billion Market Size (2024): USD 90.00 Billion CAGR (2024-2030): 5.95% Historic
Redway Power Launches High-Capacity 51.2V 420Ah Lithium Forklift Battery for Next-Level Material Handling
Redway Power Launches High-Capacity 51.2V 420Ah Lithium Forklift Battery for Nex …
Redway Power, a leading OEM lithium battery manufacturer, proudly announces the launch of its latest innovation: the 51.2V 420Ah Lithium Forklift Battery [https://www.redwaypower.com/product/48v-420ah-forklift-lithium-battery/]. Designed for modern industrial operations, this next-generation battery combines high capacity, advanced safety features, and customizable OEM/ODM solutions to revolutionize warehouse productivity and material handling efficiency. Introducing Next-Generation Power for Forklifts The new 51.2V 420Ah battery is engineered to deliver exceptional energy efficiency and durability. With a nominal energy

All 5 Releases


More Releases for RSV

The Rise In The Prevalence Of RSV Infection : A Key Catalyst Accelerating Global …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Respiratory Syncytial Virus (RSV) Therapeutics Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The market encompassing therapeutics for respiratory syncytial virus (rsv) has witnessed substantial, rapid expansion lately, projected to increase its valuation from $1.6 billion in 2024 to $2 billion just one year later
The Rise In The Prevalence Of RSV Infection : Transformative Forces Shaping the …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Will the Respiratory Syncytial Virus (RSV) Therapeutics Industry Market Size Be by 2025? The market size for therapeutics treating the respiratory syncytial virus (RSV) has seen significant expansion in the past few years. It is expected to surge from $1.6 billion in 2024 to $2 billion in 2025,
RSV Vaccine Market To Reach 731 million by 2040, Due To Increasing Awareness on …
According to our latest market report "RSV Vaccine Market, Till 2040 by Type of Vaccine, Route of Administration, Target Patient Population, Distribution Channel, Key Geographical Regions and Leading Players", the RSV Vaccine market size is projected to reach USD 731 million by 2040 from USD 1,149 million in current year, during the forecast period. To request quote of this report, please visit: https://www.rootsanalysis.com/reports/rsv-vaccine-market/request-quote.html In the dynamic landscape of preventive therapies for respiratory
Global RSV Diagnostic Products Market Size & Trends
According to a new market research report published by Global Market Estimates, the global RSV diagnostic products market is expected to grow at a CAGR of 11.4% from 2023 to 2028. Ongoing advancements in diagnostic technologies, specifically PCR and rapid point-of-care testing, play a crucial role. These advancements offer heightened accuracy, faster results, and increased accessibility, enabling prompt and precise identification of RSV infections. Browse 147 Market Data Tables and 115 Figures
Respiratory Syncytial Virus (RSV) Therapeutics Market Size to Reach USD 9080.84 …
Respiratory Syncytial Virus (RSV) Therapeutics Market Scope & Overview Respiratory Syncytial Virus (RSV) Therapeutics Market size was USD 1040.65 Million in 2022 and is expected to Reach USD 9080.84 Million by 2030 and grow at a CAGR of 31.1% over the forecast period of 2023-2030. The Respiratory Syncytial Virus (RSV) Therapeutics market is a vibrant, fiercely competitive sector that is essential to digital marketing. The demand for effective has increased as companies
Respiratory Syncytial Virus (RSV) Therapeutics Market - Conquering RSV: Advancin …
Newark, New Castle, USA: The "Respiratory Syncytial Virus (RSV) Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Respiratory Syncytial Virus (RSV) Therapeutics Market: https://www.growthplusreports.com/report/respiratory-syncytial-virus-rsv-therapeutics-market/8519 This latest report